Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therasphere (Y-90) + Systemic Therapy in Advanced Hepatocellular Carcinoma
NCT05620771Phase 2Recruiting
- Sponsor
- Northwestern University
- Start
- Nov 2022
- Primary completion
- Jul 2040
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90, atezolizumab, bevacizumab, lenvatinib, cabozantinib in hepatocellular carcinoma (HCC), sponsored by Northwestern University. Started Nov 2022; status: recruiting.
02
Drugs
yttrium-90atezolizumabbevacizumablenvatinibcabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05620771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620771.